UBS Group
KZIA

UBS Group’s Kazia Therapeutics KZIA Stock Holding History

UBS Group’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$104K Buy
13,934
+13,741
+7,120% +$95.7K ﹤0.01% 6987
2025
Q4 		$1.33K Sell
193
-3,350
-95% -$28.6K ﹤0.01% 9626
2025
Q3 		$25.5K Buy
3,543
+514
+17% +$4.27K ﹤0.01% 8005
2025
Q2 		$19K Sell
3,029
-2,228
-42% -$10.4K ﹤0.01% 8480
2025
Q1 		$20.6K Sell
5,257
-252
-5% -$1.49K ﹤0.01% 8211
2024
Q4 		$48.8K Buy
5,509
+520
+10% +$12K ﹤0.01% 7315
2024
Q3 		$107K Buy
4,989
+4,522
+968% +$90.2K ﹤0.01% 6309
2024
Q2 		$5.34K Buy
+467
New +$6.94K ﹤0.01% 8008
2024
Q1 		– Sell
-2
Closed -$44 – 9711
2023
Q4 		$44 Buy
+2
New +$59 ﹤0.01% 9003
2023
Q1 		– Sell
-127
Closed -$3.94K – 10004
2022
Q4 		$3.94K Buy
127
+50
+65% +$1.88K ﹤0.01% 9424
2022
Q3 		$4K Buy
77
+28
+57% +$3.13K ﹤0.01% 9368
2022
Q2 		$10K Buy
+49
New +$15K ﹤0.01% 7970
2022
Q1 		– Sell
-61
Closed -$26K – 10601
2021
Q4 		$26K Buy
61
+53
+663% +$26.4K ﹤0.01% 7542
2021
Q3 		$5K Buy
+8
New +$3.93K ﹤0.01% 8540
2021
Q2 		– Sell
-32
Closed -$20K – 9609
2021
Q1 		$20K Sell
32
-25
-44% -$13.1K ﹤0.01% 7385
2020
Q4 		$25K Buy
57
+31
+119% +$12.4K ﹤0.01% 6778
2020
Q3 		$9K Buy
26
+24
+1,200% +$6.76K ﹤0.01% 6934
2020
Q2 		$0 Sell
2
-171
-99% -$25K ﹤0.01% 8164
2020
Q1 		$25K Buy
173
+142
+458% +$28.1K ﹤0.01% 6349
2019
Q4 		$6K Buy
31
+29
+1,450% +$5.52K ﹤0.01% 7516
2019
Q3 		$0 Sell
2
-13
-87% -$1.78K ﹤0.01% 8128
2019
Q2 		$2K Sell
15
-16
-52% -$2.46K ﹤0.01% 7619
2019
Q1 		$5K Sell
31
-49
-61% -$8.06K ﹤0.01% 7166
2018
Q4 		$9K Sell
80
-41
-34% -$5.57K ﹤0.01% 7284
2018
Q3 		$20K Sell
121
-8
-6% -$1.36K ﹤0.01% 6795
2018
Q2 		$19K Buy
129
+110
+579% +$27.3K ﹤0.01% 6733
2018
Q1 		$5K Sell
19
-42
-69% -$9.72K ﹤0.01% 7233
2017
Q4 		$10K Buy
61
+20
+49% +$2.96K ﹤0.01% 7021
2017
Q3 		$7K Buy
41
+31
+310% +$4.92K ﹤0.01% 7070
2017
Q2 		$2K Sell
10
-35
-78% -$6.61K ﹤0.01% 7376
2017
Q1 		$12K Buy
45
+22
+96% +$6.93K ﹤0.01% 6507
2016
Q4 		$7K Buy
23
+4
+21% +$1.34K ﹤0.01% 7088
2016
Q3 		$8K Sell
19
-15
-44% -$5.84K ﹤0.01% 6912
2016
Q2 		$13K Buy
34
+24
+240% +$10.3K ﹤0.01% 6618
2016
Q1 		$5K Buy
10
+6
+150% +$2.53K ﹤0.01% 7008
2015
Q4 		$2K Sell
4
-32
-89% -$15.6K ﹤0.01% 8012
2015
Q3 		$17K Buy
36
+32
+800% +$20.7K ﹤0.01% 6850
2015
Q2 		$3K Sell
4
-46
-92% -$52.2K ﹤0.01% 8073
2015
Q1 		$43K Buy
50
+44
+733% +$25.2K ﹤0.01% 6196
2014
Q4 		$2K Buy
+6
New +$2.98K ﹤0.01% 9401

Other funds holding KZIA

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group's KZIA Position: Q1 2026 in Review

UBS Group increased its Kazia Therapeutics (KZIA) stake by 7,120% in Q1 2026, buying an estimated $95.7K and bringing the position to 13,934 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #6987.

UBS Group first reported a position in KZIA in Q4 2014 and has held it in 40 quarters since. The position peaked at $107K in Q3 2024. 23 funds tracked by Wall St. Rank hold KZIA as of Q1 2026.

  • UBS Group held 13,934 shares of Kazia Therapeutics worth $104K as of Q1 2026.
  • UBS Group bought 13,741 Kazia Therapeutics shares in Q1 2026, an estimated $95.7K.
  • Kazia Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6987 holding.
  • UBS Group first reported a position in Kazia Therapeutics in Q4 2014 and has held it in 40 quarters since.
  • UBS Group's Kazia Therapeutics position peaked at $107K in Q3 2024.
  • 23 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.